The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges
Figure 2
Classification of the high-risk breast cancer subtypes. PITX2 DNA methylation status can serve as a significant predictive biomarker for anthracycline-based chemotherapy in the two major high-risk breast cancer subtypes [44, 66].